These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 37000114)
1. Are Guideline-recommended Risk Classification Schemes in Pulmonary Hypertension Adequately Robust to Guide the Real-world Setting? Akaslan D; Aslanger E; Ataş H; Kocakaya D; Yıldızeli B; Mutlu B Balkan Med J; 2023 May; 40(3):188-196. PubMed ID: 37000114 [TBL] [Abstract][Full Text] [Related]
2. Comparison Between REVEAL Lite 2 and COMPERA 2.0 for Risk Stratification in Pulmonary Arterial Hypertension. Sahay S; Villasmil Hernandez N; Wang F; Wooten M; Nguyen DT; Fauvel C; Benza R; Graviss EA Chest; 2024 Aug; 166(2):373-387. PubMed ID: 38447640 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the European Society of Cardiology/European Respiratory Society derived three- and four-strata risk stratification models in pulmonary arterial hypertension: introducing an internet-based risk stratification calculator. Ahmed A; Ahmed S; Kempe D; Rådegran G Eur Heart J Open; 2023 Mar; 3(2):oead012. PubMed ID: 36959867 [TBL] [Abstract][Full Text] [Related]
4. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. Benza RL; Gomberg-Maitland M; Elliott CG; Farber HW; Foreman AJ; Frost AE; McGoon MD; Pasta DJ; Selej M; Burger CD; Frantz RP Chest; 2019 Aug; 156(2):323-337. PubMed ID: 30772387 [TBL] [Abstract][Full Text] [Related]
5. Comparison of Contemporary Risk Scores in All Groups of Pulmonary Hypertension: A Pulmonary Vascular Research Institute GoDeep Meta-Registry Analysis. Yogeswaran A; Gall H; Fünderich M; Wilkins MR; Howard L; Kiely DG; Lawrie A; Hassoun PM; Sirenklo Y; Torbas O; Sweatt AJ; Zamanian RT; Williams PG; Frauendorf M; Arvanitaki A; Giannakoulas G; Saleh K; Sabbour H; Cajigas HR; Frantz R; Al Ghouleh I; Chan SY; Brittain E; Annis JS; Pepe A; Ghio S; Orfanos S; Anthi A; Majeed RW; Wilhelm J; Ghofrani HA; Richter MJ; Grimminger F; Sahay S; Tello K; Seeger W; Chest; 2024 Sep; 166(3):585-603. PubMed ID: 38508334 [TBL] [Abstract][Full Text] [Related]
6. Incorporation of renal function in mortality risk assessment for pulmonary arterial hypertension. Zelt JGE; Hossain A; Sun LY; Mehta S; Chandy G; Davies RA; Contreras-Dominguez V; Dunne R; Doyle-Cox C; Wells G; Stewart DJ; Mielniczuk LM J Heart Lung Transplant; 2020 Jul; 39(7):675-685. PubMed ID: 32336606 [TBL] [Abstract][Full Text] [Related]
7. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Hoeper MM; Pausch C; Olsson KM; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Opitz C; Gibbs JSR; Delcroix M; Ghofrani HA; Park DH; Ewert R; Kaemmerer H; Kabitz HJ; Skowasch D; Behr J; Milger K; Halank M; Wilkens H; Seyfarth HJ; Held M; Dumitrescu D; Tsangaris I; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Lange TJ; Rosenkranz S Eur Respir J; 2022 Jul; 60(1):. PubMed ID: 34737226 [TBL] [Abstract][Full Text] [Related]
8. Simplified risk stratification for pulmonary arterial hypertension associated with connective tissue disease. Li X; Sun X; Huang Y; Wang Y; Yang X; Wang J; Zhang N; Gu L; Zhang M; Wang Q Clin Rheumatol; 2019 Dec; 38(12):3619-3626. PubMed ID: 31385084 [TBL] [Abstract][Full Text] [Related]
9. Assessment of Risk of Disease Progression in Pulmonary Arterial Hypertension: Insights from an International Survey of Clinical Practice. Simons JE; Mann EB; Pierozynski A Adv Ther; 2019 Sep; 36(9):2351-2363. PubMed ID: 31313097 [TBL] [Abstract][Full Text] [Related]
10. [Evaluation effect of COMPERA 2.0 risk assessment model on prognosis of Chinese patients with pulmonary arterial hypertension]. Liang YR; Yang YC; Yang BL; Zeng QX; Liu BY; Zhao Q; Luo Q; Zhao ZH; Yang T; Liu ZH; Xiong CM Zhonghua Yi Xue Za Zhi; 2023 May; 103(18):1410-1416. PubMed ID: 37150694 [No Abstract] [Full Text] [Related]
11. Risk stratification in patients with pulmonary arterial hypertension at the time of listing for lung transplantation. Vicaire H; Pavec JL; Mercier O; Montani D; Boucly A; Roche A; Pradère P; Dauriat G; Feuillet S; Pichon J; Jevnikar M; Beurnier A; Jaïs X; Fadel E; Sitbon O; Humbert M; Savale L J Heart Lung Transplant; 2022 Sep; 41(9):1285-1293. PubMed ID: 35778258 [TBL] [Abstract][Full Text] [Related]
12. Risk assessment in patients with functional class II pulmonary arterial hypertension: Comparison of physician gestalt with ESC/ERS and the REVEAL 2.0 risk score. Sahay S; Tonelli AR; Selej M; Watson Z; Benza RL PLoS One; 2020; 15(11):e0241504. PubMed ID: 33175857 [TBL] [Abstract][Full Text] [Related]
13. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. Boucly A; Weatherald J; Savale L; de Groote P; Cottin V; Prévot G; Chaouat A; Picard F; Horeau-Langlard D; Bourdin A; Jutant EM; Beurnier A; Jevnikar M; Jaïs X; Simonneau G; Montani D; Sitbon O; Humbert M Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34737227 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive Risk Assessment in Patients With Pulmonary Arterial Hypertension Referred for Lung Transplantation. Ishii S; Hatano M; Minatsuki S; Hirose K; Saito A; Yagi H; Shimbo M; Soma K; Konoeda C; Sato M; Nakajima J; Komuro I Circ J; 2024 Sep; 88(10):1610-1617. PubMed ID: 38403681 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Risk Stratification Scores in Pulmonary Arterial Hypertension: A Monocentric Retrospective Study at Lausanne University Hospital. Vraka A; Yerly P; Aubert JD Respiration; 2022; 101(6):565-576. PubMed ID: 35045412 [TBL] [Abstract][Full Text] [Related]
16. The added value of right ventricular function normalized for afterload to improve risk stratification of patients with pulmonary arterial hypertension. Vicenzi M; Caravita S; Rota I; Casella R; Deboeck G; Beretta L; Lombi A; Vachiery JL PLoS One; 2022; 17(5):e0265059. PubMed ID: 35587927 [TBL] [Abstract][Full Text] [Related]
17. Performance of risk stratification scores and role of comorbidities in older vs younger patients with pulmonary arterial hypertension. Stolfo D; Barbisan D; Ameri P; Lombardi CM; Monti S; Driussi M; Zovatto IC; Gentile P; Howard L; Toma M; Pagnesi M; Collini V; Bauleo C; Guglielmi G; Adamo M; D'Angelo L; Nalli C; Sciarrone P; Moschella M; Zorzi B; Vecchiato V; Milani M; Di Poi E; Airò E; Metra M; Garascia A; Sinagra G; Lo Giudice F J Heart Lung Transplant; 2023 Aug; 42(8):1082-1092. PubMed ID: 37005100 [TBL] [Abstract][Full Text] [Related]
18. Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension. Lewis RA; Johns CS; Cogliano M; Capener D; Tubman E; Elliot CA; Charalampopoulos A; Sabroe I; Thompson AAR; Billings CG; Hamilton N; Baster K; Laud PJ; Hickey PM; Middleton J; Armstrong IJ; Hurdman JA; Lawrie A; Rothman AMK; Wild JM; Condliffe R; Swift AJ; Kiely DG Am J Respir Crit Care Med; 2020 Feb; 201(4):458-468. PubMed ID: 31647310 [No Abstract] [Full Text] [Related]
19. Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era. Zelt JGE; Sugarman J; Weatherald J; Partridge ACR; Liang JC; Swiston J; Brunner N; Chandy G; Stewart DJ; Contreras-Dominguez V; Thakrar M; Helmersen D; Varughese R; Hirani N; Umar F; Dunne R; Doyle-Cox C; Foxall J; Mielniczuk L Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34675044 [TBL] [Abstract][Full Text] [Related]
20. Risk assessment in severe pulmonary hypertension due to interstitial lung disease. Yogeswaran A; Tello K; Faber M; Sommer N; Kuhnert S; Seeger W; Grimminger F; Ghofrani HA; Richter MJ; Gall H J Heart Lung Transplant; 2020 Oct; 39(10):1118-1125. PubMed ID: 32690230 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]